ストックスクリーナーアプリを入手
32.63
0.23%
-0.06
アフターアワーズ：
32.63
前日終値:
$32.69
開ける：
$32.67
24時間の取引高:
2.94M
Relative Volume:
0.68
時価総額：
$13.75B
収益：
$2.26B
当期純損益:
$1.09B
株価収益率:
13.93
EPS:
2.3431
ネットキャッシュフロー:
$2.70B
1週間 パフォーマンス:
-0.65%
1か月 パフォーマンス:
+0.23%
6か月 パフォーマンス:
+22.61%
1年 パフォーマンス:
+22.43%
1日の値動き範囲:
$32.57
$32.82
1週間の範囲:
$32.15
$32.93
52週間の値動き範囲:
$24.05
$34.31
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.63 | 13.94B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Tidal Investments LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Squarepoint Ops LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
State of Wyoming Has $385,000 Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Janus Henderson Group PLC Has $873,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Captrust Financial Advisors Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Investments LP Has $61.74 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Worldquant Millennium Advisors LLC - MarketBeat
University of Texas Texas AM Investment Management Co. Buys New Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Nuveen Asset Management LLC Buys 8,802 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
USS Investment Management Ltd Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Quantinno Capital Management LP - MarketBeat
Raiffeisen Bank International AG Makes New $506,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Advisers LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma - insights.citeline.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Man Group plc - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Ethic Inc. - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Trimmed by OMERS ADMINISTRATION Corp - MarketBeat
Royalty Pharma at RBC Capital Markets: Strategic Funding Insights By Investing.com - Investing.com Nigeria
Transcript : Royalty Pharma plc Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 04 - marketscreener.com
Occudo Quantitative Strategies LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
RPRX Stock Performance Following Recent Offering Details | RPRX Stock News - GuruFocus
Royalty Pharma plc (NASDAQ:RPRX) Holdings Trimmed by Captrust Financial Advisors - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Receives $42.50 Consensus PT from Analysts - Defense World
Patient Capital Management LLC Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma completes major acquisition By Investing.com - Investing.com Canada
Royalty Pharma completes major acquisition - Investing.com
Balyasny Asset Management L.P. Purchases Shares of 59,755 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Bank of America Corp DE - MarketBeat
Royalty Pharma Completes RP Management Acquisition - citybiz
Baird Financial Group Inc. Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Deutsche Bank AG Buys 847,704 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Morgan Stanley Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - Defense World
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by StockNews.com - MarketBeat
Royalty Pharma Closes Acquisition of External Manager - marketscreener.com
Royalty Pharma plc Completes Internalization of Management Structure with Overwhelming Shareholder Support - Nasdaq
Royalty Pharma Completes the Acquisition of Its External Manager - The Manila Times
Royalty Pharma Completes The Acquisition Of Its External Manager - marketscreener.com
Royalty Pharma's Major Transformation: External Manager Acquisition Promises Significant Cost Savings - Stock Titan
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Morgan Stanley reinstates Royalty Pharma with Overweight rating By Investing.com - Investing.com Nigeria
Morgan Stanley Reinstates Royalty Pharma (RPRX) at Overweight - StreetInsider
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
9.13%
1.64%
大文字化:
|
ボリューム (24 時間):